BlossomHill Therapeutics, (BLSM) news
Recent news
Blossomhill Therapeutics Inc: JP Morgan raises target price to $30 from $28
JPMorgan has updated its price target for BlossomHill Therapeutics (BLSM), raising it to $30 from $28, reflecting a positive outlook on the clinical-stage biopharmaceutical company. The stock has shown a 2.99% increase in price since the market closed, with an opening price of $26.09, which is…
AInvest Wire · Sep 21, 2026Blossomhill Therapeutics Inc: Leerink partners raises target price to $40 from $36
Leerink Partners has raised its price target for BlossomHill Therapeutics (BLSM) to $40 from $36, maintaining an "Outperform" rating for the clinical-stage biopharmaceutical company. The adjustment follows recent developments in BlossomHill’s pipeline, including updated data from its Phase 1/2…
AInvest Wire · Sep 21, 2026BlossomHill Therapeutics target raised to $40 from $30 by Guggenheim
Guggenheim Securities has raised its price target for BlossomHill Therapeutics (NASDAQ: BLSM) to $40 from $30, maintaining a "Buy" rating for the clinical-stage biopharmaceutical company. The adjustment reflects recent developments in BlossomHill’s pipeline, including updated data from its Phase…
AInvest Wire · Sep 21, 2026Blossomhill Therapeutics - Q2 2026 net loss $23.80 mln, $-8.75 per share
BlossomHill Therapeutics, Inc. (NASDAQ: BLSM) reported a net loss of $23.80 million, or $8.75 per share, for the second quarter of 2026, according to preliminary estimates. This result reflects continued financial challenges for the clinical-stage biopharmaceutical company, which remains focused on…
AInvest Wire · Sep 18, 2026Blossomhill Therapeutics, Inc.: H.C. Wainwright initiates coverage with buy rating and target price $35
H.C. Wainwright & Co. has initiated coverage of BlossomHill Therapeutics, Inc. (NASDAQ: BLSM) with a "Buy" rating and a target price of $35 per share . The decision follows BlossomHill’s recent initial public offering (IPO), which priced at $16.00 per share for 9,375,000 shares, generating $150.0…
AInvest Wire · Sep 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.